2m 2m 2m 2m 2m 2m 2m
SAB BIOTHERAP (SABS)
NASDAQ
$3.53+$0.12 (+3.52%)
Price as of Sep 11, 2026 7:30 PM EDT- $310.3MMarket Cap
- 60.85%1-Year Change
- BiotechnologyIndustry
SAB BIOTHERAP (SABS)
$3.53+$0.12 (+3.52%)
SABS | vs History | vs S&P 500 | |
|---|---|---|---|
General Statistics | |||
Latest Close | $3.41 | ||
Change | -$0.010 (-0.29%) | ||
Open | $3.45 | ||
High | $3.54 | ||
Low | $3.38 | ||
Previous Close | $3.42 | ||
Volume | 712,045 | ||
30-Day Average Volume | 304,958 | ||
1-Week Change | -8.33% | ||
1-Month Change | -9.31% | ||
1-Year Change | 60.85% | ||
3-Year Change | -44.19% | ||
5-Year Change | N/A | ||
Fundamentals | |||
Shares Outstanding | 91.0M | ||
Total Assets | $238.2M | ||
Market Cap | $310.3M | ||
Enterprise Value | $302.0M | ||
Period: QTR TTM FY | |||
Revenue | N/A | ||
Net Income | -$22.5M | ||
Free Cash Flow | -$11.4M | ||
EBIT | -$22.5M | ||
EBITDA | -$21.7M | ||
Net Working Capital | $96.2M | ||
EPS | -$0.28 | ||
Enterprise Value/EBITDA | -14 | ||
Enterprise Value/Revenue | N/A | ||
P/B | 1 | ||
P/E | -12 | ||
PEG | -1 | ||
Price/Free Cash Flow | -27 | ||
Price/Operating Cash Flow | -32 | ||
Dividends & Splits | |||
Forward Annual Dividend Yield | N/A | ||
Trailing Annual Dividend Yield | N/A | ||
Ex-Dividend Date | N/A | ||
Last Split Factor | 1 : 10 | ||
Last Split Date | 01/05/2024 | ||
Earnings & Revenue